Welcome to BioMarin's Online Press Room.
We've brought together a variety of information in one location
to better assist you in your efforts to research and develop
news articles. Should you require additional information, please
call or e-mail us any time.
BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome... MORE >FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)... MORE >BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York... MORE >